Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 95
Filter
2.
Int J Dermatol ; 2024 May 10.
Article in English | MEDLINE | ID: mdl-38727096

ABSTRACT

BACKGROUND: We aimed to investigate the prevalence of skin disease among patients with systemic lupus erythematosus (SLE) and determine whether LE skin disease had clinical or serologic correlates with SLE. METHODS: We reviewed records of 335 patients with SLE (seen at Mayo Clinic, Rochester, Minnesota, USA) and abstracted skin manifestations, fulfilled mucocutaneous SLE criteria, and clinical and serologic parameters. RESULTS: Of the 231 patients with skin manifestations, 57 (24.7%) had LE-specific conditions, 102 (44.2%) had LE-nonspecific conditions, and 72 (31.2%) had both. LE skin disease was associated with photosensitivity, anti-Smith antibodies, and anti-U1RNP antibodies (all P < 0.001). Patients without LE skin disease more commonly had elevated C-reactive protein levels (P = 0.01). Patients meeting 2-4 mucocutaneous American College of Rheumatology criteria less commonly had cytopenia (P = 0.004) or anti-double-stranded DNA antibodies (P = 0.004). No significant associations were observed for systemic involvement (renal, hematologic, neurologic, and arthritis) when comparing patients with or without LE skin involvement. LE skin involvement was not significantly associated with internal SLE disease flare, number of medications, or overall survival. CONCLUSIONS: LE skin disease commonly occurs in patients with SLE. The presence of LE skin disease had no mitigating impact on the severity of SLE sequelae, disease flares, number of medications, or overall survival.

3.
Pediatr Dermatol ; 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38561464

ABSTRACT

A 4-month-old male presented for a large, hypertrichotic brown patch on the upper back with several scattered 0.5-1.5 cm, round to oval, brown macules and patches on the trunk and extremities. The lesion was initially diagnosed as a giant congenital melanocytic nevus based on clinical exam and histopathology with immunohistochemical stains. The patient was later diagnosed with neurofibromatosis type 1, and the lesion on the back developed a "bag of worms" texture consistent with a plexiform neurofibroma and found to harbor a pathogenic variant in the NF1 gene. This case highlights the diagnostic challenge of differentiating these lesions and their overlapping clinical and histopathological features.

5.
Dermatol Clin ; 42(2): 219-229, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38423683

ABSTRACT

Neutrophilic urticarial dermatosis (NUD) is a rare form of dermatosis that is poorly understood. It was first described by Kieffer and colleagues as an urticarial eruption that is histopathologically characterized by a perivascular and interstitial neutrophilic infiltrate with intense leukocytoclasia and without vasculitis or dermal edema. NUD clinically presents as a chronic or recurrent eruption that consists of nonpruritic macules, papules, or plaques that are pink to reddish and that resolve within 24 hours without residual pigmentation. NUD is often associated with systemic diseases such as Schnitzler syndrome, lupus erythematosus, adult-onset Still's disease, and cryopyrin-associated periodic syndromes.


Subject(s)
Exanthema , Lupus Erythematosus, Systemic , Schnitzler Syndrome , Still's Disease, Adult-Onset , Urticaria , Adult , Humans , Skin , Urticaria/diagnosis , Urticaria/complications , Schnitzler Syndrome/complications , Schnitzler Syndrome/diagnosis , Schnitzler Syndrome/drug therapy , Lupus Erythematosus, Systemic/complications , Still's Disease, Adult-Onset/complications , Still's Disease, Adult-Onset/diagnosis
6.
Digit Health ; 10: 20552076241234581, 2024.
Article in English | MEDLINE | ID: mdl-38410791

ABSTRACT

Background: Delivery of dermatologic care through telemedicine was accelerated by the COVID-19 pandemic. We sought to analyze the teledermatology experience across Mayo Clinic's health care system to identify strengths and limitations of teledermatology. Methods: Electronic health records of dermatology televisits were reviewed from multiple U.S. Mayo Clinic sites from January 2020 through January 2021. Results: A total of 13,181 dermatology televisits were conducted in 6468 unique patients. Patients were primarily female (60.2%), and mean age of all patients was 34.1 years. Synchronous / live video conferencing visits were the most common (40.0%) telecare modality. Synchronous / live audio conferencing and asynchronous / store-and-forward visits comprised 33.0% and 27.0% of appointments. In total, 3944 televisits (29.9%) were successfully concluded via a single appointment. An in-person appointment was needed for 1693 patients (26.2%) after their initial televisit. For patients with a single televisit, synchronous / live video conferencing was the most common virtual modality (58.0% vs 32.2% of patients with multiple visits, p < 0.001). Patients needing in-person follow-up visits were slightly older than those who did not (mean [SD], 38.8 [22.3] vs 35.0 [23.6] years; p < 0.001) but without any sex-based difference. Around one-third of patients needed an in-person follow-up visit after their initial asynchronous / store-and-forward visit which was higher when compared with synchronous / live audio and video conferencing. Conclusion: Single dermatology televisits effectively managed nearly one-third of patients who did not require in-person follow-up. An initial synchronous / live video conferencing was more likely to yield a single clinical encounter, whereas asynchronous / store-and-forward visits required more in-person follow-up. Future studies are required that focus on dermatology-specific cost, diagnoses, access, quality of care, and outcomes.

7.
Int J Dermatol ; 63(5): 557-559, 2024 May.
Article in English | MEDLINE | ID: mdl-38357960

ABSTRACT

As the US population becomes increasingly diverse, more patients of color seek dermatologic care and often have concerns that are unique to their skin color. Therefore, it is critically important that the knowledge gap in skin of color dermatology be urgently addressed. In addition to addressing the clinical gap in recognizing dermatologic disease in patients of color, the role of dermatopathology in bridging this gap remains unaddressed. Given the impact that skin color can have on the presentation and subsequent management of dermatologic diseases, understanding the current knowledge of the unique structural and histologic characteristics in skin of color may help give us insight on the role skin color should play in histopathologic diagnosis. In this paper, we bring insights into the role dermatopathology plays in addressing our knowledge of cutaneous disease in patients with skin of color. After we highlight issues to consider, we can begin to identify gaps in knowledge that still exist within dermatopathology that need to be addressed to ensure patients of all backgrounds receive equitable dermatologic care.


Subject(s)
Dermatology , Skin Diseases , Skin Pigmentation , Humans , Skin Diseases/pathology , Skin Diseases/diagnosis , Dermatology/education , Skin/pathology , Skin Neoplasms/pathology , Skin Neoplasms/diagnosis
9.
Int J Dermatol ; 63(1): 5-9, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37888765

ABSTRACT

Toxic epidermal necrolysis (TEN) is a rare but often lethal drug reaction involving the skin. Treatment is often centered around suppurative care, and the mortality rate remains unacceptably high, although the clinical and epidemiological features of TEN have been well documented for decades. Recent studies have placed an emphasis on certain medications in the pathophysiology of severe TEN, and our colleagues previously reported several cases of clinical improvement in TEN patients following hemodialysis. Here, we discuss the major considerations for initiating dialysis in TEN patients. By doing so, we hope to encourage others to explore this potential avenue for treating TEN, one of the most serious medical emergencies in the field of dermatology.


Subject(s)
Stevens-Johnson Syndrome , Humans , Stevens-Johnson Syndrome/drug therapy , Stevens-Johnson Syndrome/etiology , Renal Dialysis , Skin
10.
Clin Geriatr Med ; 40(1): 37-74, 2024 02.
Article in English | MEDLINE | ID: mdl-38000862

ABSTRACT

Bullous diseases are a group of dermatoses primarily characterized by the presence of vesicles (0.1-0.9 cm) or bullae (>1 cm). There are various categories of bullous disease: allergic, autoimmune, infectious, mechanical, and metabolic. These diseases affect individuals in all decades of life, but older adults, age 65 and older, are particularly susceptible to bullous diseases of all etiologies. The incidence of these disorders is expected to increase given the advancing age of the general population. In this comprehensive review, we will outline the common bullous diseases affecting older individuals and provide an approach to evaluation and management.


Subject(s)
Skin Diseases, Vesiculobullous , Humans , Aged , Skin Diseases, Vesiculobullous/diagnosis , Skin Diseases, Vesiculobullous/etiology , Skin Diseases, Vesiculobullous/therapy
11.
Am J Dermatopathol ; 46(3): 175-178, 2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38153267

ABSTRACT

ABSTRACT: Mammary Paget disease is a rare form of breast cancer, which typically presents as an eczematous plaque on the nipple or surrounding skin. It is often a clinical diagnosis that is confirmed with skin biopsy. Histologic hallmarks of mammary Paget disease include large, pleomorphic, malignant, ductal epithelial cells within the epidermis. Chronic lichenoid inflammation may be seen in the papillary dermis but is not diagnostic. Because mammary Paget disease often overlies ductal carcinoma in situ or invasive carcinoma of the breast, prompt bilateral mammography is warranted. We report a case of Paget disease of the nipple with negative breast imaging that was originally misdiagnosed due to a dense lichenoid infiltrate obscuring the neoplasm.


Subject(s)
Adenocarcinoma , Breast Neoplasms , Carcinoma , Paget's Disease, Mammary , Humans , Female , Paget's Disease, Mammary/diagnosis , Paget's Disease, Mammary/pathology , Breast Neoplasms/pathology , Carcinoma/pathology , Skin/pathology , Adenocarcinoma/pathology , Nipples/pathology , Inflammation/pathology
12.
Mayo Clin Proc ; 98(12): 1875-1887, 2023 Dec.
Article in English | MEDLINE | ID: mdl-38044003

ABSTRACT

In the past few years, there have been rapid advances in technology and the use of digital tools in health care and clinical research. Although these innovations have immense potential to improve health care delivery and outcomes, there are genuine concerns related to inadvertent widening of the digital gap consequentially exacerbating health disparities. As such, it is important that we critically evaluate the impact of expansive digital transformation in medicine and clinical research on health equity. For digital solutions to truly improve the landscape of health care and clinical trial participation for all persons in an equitable way, targeted interventions to address historic injustices, structural racism, and social and digital determinants of health are essential. The urgent need to focus on interventions to promote health equity was made abundantly clear with the coronavirus disease 2019 pandemic, which magnified long-standing social and racial health disparities. Novel digital technologies present a unique opportunity to embed equity ideals into the ecosystem of health care and clinical research. In this review, we examine racial and ethnic diversity in clinical trials, historic instances of unethical research practices in biomedical research and its impact on clinical trial participation, and the digital divide in health care and clinical research, and we propose suggestions to achieve digital health equity in clinical trials. We also highlight key digital health opportunities in cardiovascular medicine and dermatology as exemplars, and we offer future directions for development and adoption of patient-centric interventions aimed at narrowing the digital divide and mitigating health inequities.


Subject(s)
Clinical Trials as Topic , Digital Divide , Healthcare Disparities , Humans , COVID-19/epidemiology , Health Promotion
13.
Am J Dermatopathol ; 45(12): 828-830, 2023 Dec 01.
Article in English | MEDLINE | ID: mdl-37883967

ABSTRACT

ABSTRACT: Cutaneous metastasis from prostate cancer is a rare manifestation, occurring in less than 1% of all cases of prostate cancer. Prostate cancer metastasis occurs most often in lymph nodes and bones. In this study, we present the case of a 55-year-old man with prostate adenocarcinoma and progressive papules on his left chest that developed shortly after androgen deprivation therapy was initiated. This case emphasizes the significance of considering cutaneous metastasis in the diagnostic differential when assessing patients with a history of cancer and the need to thoroughly evaluate these cases.


Subject(s)
Adenocarcinoma , Carcinoma , Exanthema , Genital Neoplasms, Female , Prostatic Neoplasms , Skin Neoplasms , Male , Female , Humans , Middle Aged , Androgen Antagonists/therapeutic use , Prostate
15.
J Pediatr ; 262: 113661, 2023 11.
Article in English | MEDLINE | ID: mdl-37543282
17.
Dermatol Clin ; 41(3): 435-454, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37236713

ABSTRACT

Collagen vascular diseases such as lupus erythematosus and dermatomyositis (DM) occur 2 to 3 times more often among patients with skin of color. In this article, the authors review DM and cutaneous lupus erythematosus, including acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, and discoid lupus erythematosus. They discuss the distinguishing features between these entities and highlight distinct presentations and management considerations in patients with skin of color to aid in prompt and correct diagnoses in this patient population.


Subject(s)
Dermatomyositis , Lupus Erythematosus, Cutaneous , Lupus Erythematosus, Discoid , Lupus Erythematosus, Systemic , Vascular Diseases , Humans , Dermatomyositis/diagnosis , Skin Pigmentation , Skin , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Discoid/diagnosis , Collagen
18.
Hum Pathol ; 140: 240-266, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37146946

ABSTRACT

Skin of color (SoC) remains an understudied and under taught area of dermatology despite its rising importance. Race and ethnicity play a particularly important role in dermatology as skin pigmentation can affect the manifestation and presentation of many common dermatoses. With this review, we seek to review pertinent differences in SoC histology, as well as highlight the histopathology of conditions more common in SoC and address inherent bias that may affect accurate dermatopathology sign out.

19.
Dermatol Surg ; 49(7): 649-653, 2023 07 01.
Article in English | MEDLINE | ID: mdl-37093678

ABSTRACT

BACKGROUND: Chromoblastomycosis is an uncommon fungal infection of the skin caused by a variety of dematiaceous fungal species that is typically contracted through direct inoculation into the skin. OBJECTIVE: To collect and examine data pertaining to the clinical presentation and management of patients with chromoblastomycosis. METHODS: Through a retrospective study, a pathology medical record search was performed from January 2004 to December 2020 at a single institution. RESULTS: A total of 9 patients were identified. Seven of 9 cases occurred in solid organ transplant recipients. All cases were located on the extremities. Six of 9 cases were clinically suspected to be squamous cell carcinoma. Seven of 9 cases were treated with surgical excision. Six of 9 patients were treated with oral antifungal medication. Four of 9 patients had received combination therapy. Eight of 9 patients had no recurrence of the disease after treatment. CONCLUSION: Chromoblastomycosis presents as verrucous papules or nodules and may clinically and histopathologically mimic squamous cell carcinoma. Immunosuppression is likely a risk factor for the development of chromoblastomycosis. This study highlights the importance of clinical awareness of this disease's clinical presentation and prevalence in immunosuppressed patient populations.


Subject(s)
Carcinoma, Squamous Cell , Chromoblastomycosis , Dermatomycoses , Humans , Chromoblastomycosis/diagnosis , Chromoblastomycosis/drug therapy , Chromoblastomycosis/surgery , Retrospective Studies , Antifungal Agents/therapeutic use , Carcinoma, Squamous Cell/surgery , Carcinoma, Squamous Cell/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...